Rapid Medical has announced new clinical data demonstrating the “significant advantages” of its novel Comaneci embolisation assist device over established techniques to treat ruptured wide-neck intracranial aneurysms.
A recent meta-analysis published in World Neurosurgery found that Comaneci is associated with lower haemorrhagic and thromboembolic complication rates, higher complete occlusion rates, and similar residual retreatment rates, as compared to stent-assisted and balloon-assisted coiling techniques.
“The Comaneci device is a highly useful adjunct tool for patients with subarachnoid haemorrhage,” said study author Adnan Siddiqui (University at Buffalo/Jacobs Institute, Buffalo, USA). “While stent-assisted coiling [SAC] and balloon-assisted coiling [BAC] are widely used therapies, each method has unique drawbacks that are nicely addressed with the Comaneci device.”
As the only adjustable, non-occlusive device for haemorrhagic stroke treatment—so claims a Rapid Medical press release—Comaneci’s visible mesh conforms to the anatomy, providing stent-like support without the complications of a permanent stent or halting blood flow like a balloon. It has been used in over 12,000 procedures worldwide in wide-neck aneurysm treatments and, in Europe only, to open arteries constricted by vasospasm.
In their recently published meta-analysis, researchers at the University at Buffalo and George Washington University (Washington DC, USA) compared the three devices by pooling more than 3,200 ruptured aneurysm cases across 64 studies.
No significant differences were found between SAC and BAC. However, Comaneci-assisted coiling showed significantly lower thromboembolic and aneurysmal complication rates, and periprocedural complications, than both SAC and BAC. Furthermore, it demonstrated statistically better complete occlusion rates versus SAC and equivalent rates to BAC, the Rapid Medical release also states.
